For the quarter ended March 2025, Merit Medical (MMSI) reported revenue of $355.35 million, up 9.8% over the same period last year. EPS came in at $0.86, compared to $0.77 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $352.33 million, representing a surprise of +0.86%. The company delivered an EPS surprise of +14.67%, with the consensus EPS estimate being $0.75.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Merit Medical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Geographic Sales- United States: $213.56 million compared to the $208.66 million average estimate based on two analysts. The reported number represents a change of +14.8% year over year.
• Geographic Sales- International: $141.79 million versus $143.33 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +3.2% change.
• Revenue- Cardiovascular- Peripheral Intervention: $137.28 million versus the six-analyst average estimate of $141.95 million. The reported number represents a year-over-year change of +2%.
• Revenue- Cardiovascular- Cardiac Intervention: $99.74 million versus $98.79 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +10% change.
• Revenue- Endoscopy: $16.64 million versus the six-analyst average estimate of $17.89 million. The reported number represents a year-over-year change of +64.2%.
• Revenue- Cardiovascular- OEM: $53.75 million compared to the $43.84 million average estimate based on six analysts. The reported number represents a change of +36.9% year over year.
• Revenue- Cardiovascular: $338.71 million versus $334.45 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +8.1% change.
• Revenue- Cardiovascular- Custom Procedural Solutions: $47.94 million versus the six-analyst average estimate of $49.74 million. The reported number represents a year-over-year change of -1.8%.

View all Key Company Metrics for Merit Medical here>>>

Shares of Merit Medical have returned -9.6% over the past month versus the Zacks S&P 500 composite's -5.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research